Design of Biodegradable Nanoparticles for Oral Delivery of Doxorubicin: In vivo Pharmacokinetics and Toxicity Studies in Rats
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Purpose Doxorubicin, a potent anticancer drug associated with cardiotoxicity and low oral bioavailability, was loaded into nanoparticles with a view to improve its performance.Methods Doxorubicin loaded PLGA nanoparticles were prepared by a double emulsion method. The pH dependent stability of nanoparticles in simulated fluids was evaluated. DSC and XRD studies were carried out in order to ascertain the nature of doxorubicin in formulations in conjunction with accelerated stability studies. The in vitro release was investigated in phosphate buffer. The pharmacokinetic and toxicity studies were conducted in rats.Results Nanoparticles had an average size of 185 nm, with 49% entrapment at 10% w/w of polymer. The particles displayed good pH dependent stability in the pH range 1.1-7.4. DSC and XRD studies revealed the amorphous nature of doxorubicin in nanoparticles and the accelerated stability studies revealed the integrity of formulations. Initial biphasic release (20%) followed by a sustained release (80%) for 24 days was observed under in vitro conditions. The doxorubicin loaded nanoparticles demonstrated superior performance in vivo as evident by enhanced bioavailability and lower toxicity.Conclusions Together, the data indicates the potential of doxorubicin loaded nanoparticles for oral chemotherapy. Further, these formulations could be explored for new indications like leishmaniasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It was reported that the bioavailability of chemotherapeutic drugs, such as tamoxifen or doxorubicin, encapsulated in particles significantly increased [83–84].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [83]
Citations
Cites
Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction
Ohkawa, H., Ohishi, N., & Yagi, K. (1979) · Analytical Biochemistry · doi:10.1016/0003-2697(79)90738-3 · Cited by 29,297 · cited 1×
“The MDA content, a measure of lipid peroxidation, was assayed in the form of thiobarbituric acid reacting substances assay (TBARS) (23).”
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778 · cited 1×
“However, its therapeutic effects are limited due to its dose dependent cardiotoxicity and myelosuppression (10,11).”
Blacklow, N. R., Gorbach, S. L., & Bartlett, J. G. (1992) · Cited by 2,753
Gewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240 · cited 1×
“It is widely accepted that oxidative stress and the production of free radicals are involved in doxorubicin action, both in terms of antitumor effects and cardiotoxicity (28).”
Expression of Multidrug Resistance Gene in Human Cancers
Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S.-L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., et al. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.2.116 · Cited by 1,290 · cited 1×
“ability of doxorubicin is less because it is eliminated by the first-pass extraction of the cytochrome P450-dependent metabolic process and the over expression of the multidrug efflux pump transporter P-glycoprotein (P-gp), which is rich in the intestine, liver and kidney, thus making it difficult to administer doxoru…”
The Anthracycline Antineoplastic Drugs
Young, R. C., Ozols, R. F., & Myers, C. E. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107163050305 · Cited by 793 · cited 1×
“Doxorubicin, an anthracycline antibiotic and one of the most widely used anticancer agents, shows high antitumor activity (8,9).”
PLGA Nanoparticles in Drug Delivery: The State of the Art;
Bala, I., Hariharan, S., & Kumar, M. R. (2004) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v21.i5.20 · Cited by 739 · cited 1×
“Moreover, the loaded drug can be released from the nanoparticles in a controlled fashion at a desired rate over a sufficiently long duration (18,19) thereby increasing the overall pay load of drug to cancerous cells.”
Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice
Carpenter, J. F., Pikal, M. J., Chang, B. S., & Randolph, T. W. (1997) · Pharmaceutical Research · doi:10.1023/a:1012180707283 · Cited by 683 · cited 1×
“The glassy state is characterized by a high viscosity which lowers the mobility of molecules and thus prevents the aggregation (26,27).”
Niwa, T., Takeuchi, H., Hino, T., Kunou, N., & Kawashima, Y. (1993) · Journal of Controlled Release · doi:10.1016/0168-3659(93)90097-o · Cited by 483
Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs
Dong, Y., & Feng, S.-S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.03.021 · Cited by 395
Feng, S.-S., & Chien, S. (2003) · Chemical Engineering Science · doi:10.1016/s0009-2509(03)00234-3 · Cited by 364 · cited 1×
“It is generally believed that long-term exposure to drug at modest concentrations would be more beneficial than a pulsed supply of the drug at higher concentrations (1).”
P-Glycoproteins and Multidrug Resistance
Bellamy, W. T. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.001113 · Cited by 319 · cited 1×
“ability of doxorubicin is less because it is eliminated by the first-pass extraction of the cytochrome P450-dependent metabolic process and the over expression of the multidrug efflux pump transporter P-glycoprotein (P-gp), which is rich in the intestine, liver and kidney, thus making it difficult to administer doxoru…”
Adriamycin cardiomyopathy: pathophysiology and prevention
Singal, P. K., Iliskovic, N., Li, T., & Kumar, D. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.12.9337145 · Cited by 310
Oral chemotherapy: rationale and future directions.
DeMario, M. D., & Ratain, M. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2557 · Cited by 293
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
Ryberg, M., Nielsen, D., Skovsgaard, T., Hansen, J., Jensen, B. V., & Dombernowsky, P. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3502 · Cited by 289
Zhang, Z., & Feng, S.-S. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2005.05.104 · Cited by 240
Scholes, P. D., Coombes, A. G. A., Illum, L., Daviz, S. S., Vert, M., & Davies, M. C. (1993) · Journal of Controlled Release · doi:10.1016/0168-3659(93)90103-c · Cited by 208
Italia, J. L., Bhatt, D. K., Bhardwaj, V., Tikoo, K., & Kumar, M. N. V. R. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.02.004 · Cited by 203 · cited 1×
“Nanoparticles prepared from biodegradable polymers seem to be a promising approach that can provide drug delivery system for oral chemotherapy with high therapeutic efficacy and better profile in terms of adverse effects (17).”
Malingré, M. M., Beijnen, J. H., & Schellens, J. H. M. (2001) · Investigational New Drugs · doi:10.1023/a:1010635000879 · Cited by 158 · cited 1×
“Recently, there has been a surge in the development of oral chemotherapeutic agents and many molecules are undergoing clinical trails or already approved for their oral efficacy (7).”
Zimmermann, E., & Müller, R. H. (2001) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(01)00167-9 · Cited by 151 · cited 1×
“4 and SIF the samples were assessed after 6 h (22).”
Bromberg, L. E., & Alakhov, V. Y. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00419-4 · Cited by 112 · cited 1×
“Toxicity associated with these anticancer agents and their poor biopharmaceutical properties has lead to numerous attempts in developing more rational formulations for chemotherapy (2) and the most successful has been DOXIL®.”
Development of Multidrug-Resistance Convertors: Sense or Nonsense?
van Zuylen, L., Nooter, K., Sparreboom, A., & Verweij, J. (2000) · Investigational New Drugs · doi:10.1023/a:1006487003814 · Cited by 83
Kole, L., Das, L., & Das, P. K. (1999) · The Journal of Infectious Diseases · doi:10.1086/314929 · Cited by 75
Pharmaceutical Aspects of Polymeric Nanoparticles for Oral Drug Delivery
Bhardwaj, V., Hariharan, S., Bala, I., Lamprecht, A., Kumar, N., Panchagnula, R., & Kumar, M. N. V. R. (2005) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2005.033 · Cited by 58 · cited 1×
“Moreover, the loaded drug can be released from the nanoparticles in a controlled fashion at a desired rate over a sufficiently long duration (18,19) thereby increasing the overall pay load of drug to cancerous cells.”
Italia, J. L., Datta, P., Ankola, D. D., & Kumar, M. N. V. R. (2008) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2008.341 · Cited by 41 · cited 1×
“Due to high aqueous solubility of doxorubicin, double emulsion method was adopted for particles preparation with appropriate modifications (21).”
The Effect of Carbohydrate Additives in the Freeze-Drying of Alkaline Phosphatase
Ford, A. W., & Dawson, P. J. (1993) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1993.tb03689.x · Cited by 38 · cited 1×
“The glassy state is characterized by a high viscosity which lowers the mobility of molecules and thus prevents the aggregation (26,27).”
Welcome to the Journal of Biomedical Nanotechnology
Kumar, C. S. S. R. (2005) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2005.015 · Cited by 25
Gonsette, R. E. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.4.747 · Cited by 15 · cited 1×
“Hence, doxorubicin becomes indispensable when it comes to cancer chemotherapy (12,13).”
On prejudice and facts and choices
Köhne, C.-H., & Folprecht, G. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj142 · Cited by 7 · cited 1×
“Classical anti-neoplastic drugs have been available as oral medications for some time and many of these compounds are analogues of their parenteral counterparts (3).”
Research works printed but not linked: 1
- S. K. Carter. Adriamycin—thoughts for the future. Chemother. Rep. Cancer. 63:877–883 (1975).
Cited by
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
Acharya, S., & Sahoo, S. K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.10.008 · Cited by 1,112
Transport of drugs across the blood–brain barrier by nanoparticles.
Wohlfart, S., Gelperina, S., & Kreuter, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.017 · Cited by 715
Polymeric nanoparticles: Promising platform for drug delivery
El-Say, K. M., & El-Sawy, H. S. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.06.052 · Cited by 608
“In addition, PNPs proved to have the potential to enhance drug stability, prolong remediation outcome, amended cellular uptake and diminish degradation as well as metabolism (He et al., 2012; Kalaria et al., 2009).”
BackgroundInfluentialPLGA-Based Nanoparticles as Cancer Drug Delivery Systems
Tabatabaei Mirakabad, F. S., Nejati-Koshki, K., Akbarzadeh, A., Yamchi, M. R., Milani, M., Zarghami, N., Zeighamian, V., Rahimzadeh, A., Alimohammadi, S., Hanifehpour, Y., et al. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.2.517 · Cited by 542
Metadata
- Authors
- Kalaria, D. R., Sharma, G., Beniwal, V., & Ravi Kumar, M. N. V.
- Affiliations
- National Institute of Pharmaceutical Education and Research (IN)
- University of Strathclyde (GB)
- Venue
- Pharmaceutical Research
- Published
- 2008-11-08
- Volume
- 26
- Issue
- 3
- Pages
- 492-501
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W2050181086
- Cited by
- 246
- References
- 29
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 15 · 2023: 3 · 2022: 7 · 2021: 10 · 2020: 17 · 2019: 18 · 2018: 15 · 2017: 16 · 2016: 15 · 2015: 20 · 2014: 20 · 2013: 28 · 2012: 19
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (submittedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- doxorubicin, PLGA nanoparticles, oral drug delivery, oral bioavailability, pharmacokinetics, toxicity, pH-dependent stability, sustained drug release, amorphous drug, cardiotoxicity, leishmaniasis
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Administration, Oral, Animals, Antibiotics, Antineoplastic, Biocompatible Materials, Biological Availability, Calorimetry, Differential Scanning, Doxorubicin, Drug Carriers, Drug Stability, Female, Hydrogen-Ion Concentration, Particle Size, Polyglycolic Acid, Solubility, Surface Properties, X-Ray Diffraction, Drug Design, Rats, Sprague-Dawley, Lactic Acid, Rats, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.